|
NEWS RELEASE
HIV research yields potential drug target
Corey Yu, PhD, laboratory of Dmitri Ivanov, PhD
February 10, 2021 - Humans possess a formidable multi-layered defense system that protects us against viral infections. Better understanding of these defenses and the tricks that viruses use to evade them could open novel avenues for treating viral infections and possibly other diseases.
For example, a human protein called SAMHD1 impedes replication of the human immunodeficiency virus (HIV) and other viruses by depleting deoxynucleotides — building blocks needed for the replication of the viral genome. It has long remained a mystery whether and how this protein is activated in response to infection.
Now researchers from UT Health San Antonio have discovered that SAMHD1 recognizes a unique molecular pattern in nucleic acids. This pattern, called “phosphorothioation,” may act as a signal for action. It’s like a sentinel atop a palace wall who sees an invading horde in the distance and calls the troops to battle stations.
Understanding the mechanism of SAMHD1 activation could be a step forward in the fight against HIV/AIDS.
“If we are able to increase SAMHD1 activity using a specific drug, that could potentially have anti-HIV activity,” said Corey H. Yu, PhD, postdoctoral fellow in the laboratory of Dmitri Ivanov, PhD, at UT Health San Antonio.
Today’s antivirals target the viral proteins. If, in addition, therapies could unleash the power of our existing immune defenses on the virus to help eliminate it from the body, that could be a game-changer.
“It’s a different way to look at antiviral drugs,” Dr. Yu said. “We want to know if we can try to target a protein to hopefully boost its activity against HIV.”
###
Dr. Yu is first author of the study findings published Feb. 2 by the journal Nature Communications. The National Institutes of Health funded the research.
Nucleic acid binding by SAMHD1 contributes to the antiretroviral activity and is enhanced by the GpsN modification.
Corey H. Yu, Akash Bhattacharya, Mirjana Persaud, Alexander B. Taylor, Zhonghua Wang, Angel Bulnes-Ramos, Joella Xu, Anastasia Selyutina, Alicia Martinez-Lopez, Kristin Cano, Borries Demeler, Baek Kim, Stephen C. Hardies, Felipe Diaz-Griffero and Dmitri N. Ivanov.
First published: Feb. 2, 2021, Nature Communications
https://doi.org/10.1038/s41467-021-21023-8
###
The University of Texas Health Science Center at San Antonio, also referred to as UT Health San Antonio, is one of the country’s leading health sciences universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have graduated more than 37,000 alumni who are leading change, advancing their fields, and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways “We make lives better®,” visit www.uthscsa.edu.
Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.
Media Contact
Will Sansom
sansom@uthscsa.edu
210-567-2579
@UTHealthSA
http://www.uthscsa.edu/hscnews
Source: https://news.uthscsa.edu/hiv-research-yields-potential-drug-target/
"Reproduced with permission - "UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO"
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
|
